PE20211545A1 - Dosis unitaria de vacuna contra el dengue y administracion de esta - Google Patents
Dosis unitaria de vacuna contra el dengue y administracion de estaInfo
- Publication number
- PE20211545A1 PE20211545A1 PE2021000288A PE2021000288A PE20211545A1 PE 20211545 A1 PE20211545 A1 PE 20211545A1 PE 2021000288 A PE2021000288 A PE 2021000288A PE 2021000288 A PE2021000288 A PE 2021000288A PE 20211545 A1 PE20211545 A1 PE 20211545A1
- Authority
- PE
- Peru
- Prior art keywords
- dengue
- tdv
- unit dose
- against dengue
- safe
- Prior art date
Links
- 208000025729 dengue disease Diseases 0.000 title abstract 10
- 208000001490 Dengue Diseases 0.000 title abstract 7
- 206010012310 Dengue fever Diseases 0.000 title abstract 7
- 229960005486 vaccine Drugs 0.000 title abstract 5
- 238000000034 method Methods 0.000 abstract 4
- 238000011081 inoculation Methods 0.000 abstract 2
- 241000725619 Dengue virus Species 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000000405 serological effect Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18192814 | 2018-09-05 | ||
| EP18192800 | 2018-09-05 | ||
| EP18192717 | 2018-09-05 | ||
| EP18192711 | 2018-09-05 | ||
| EP18192787 | 2018-09-05 | ||
| EP18192793 | 2018-09-05 | ||
| EP18192776 | 2018-09-05 | ||
| EP18192701 | 2018-09-05 | ||
| EP19154334 | 2019-01-29 | ||
| EP19161184 | 2019-03-07 | ||
| US16/295,611 US11464815B2 (en) | 2018-09-05 | 2019-03-07 | Dengue vaccine unit dose and administration thereof |
| PCT/US2019/049749 WO2020051334A1 (en) | 2018-09-05 | 2019-09-05 | Dengue vaccine unit dose and administration thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211545A1 true PE20211545A1 (es) | 2021-08-16 |
Family
ID=69722836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000288A PE20211545A1 (es) | 2018-09-05 | 2019-09-05 | Dosis unitaria de vacuna contra el dengue y administracion de esta |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11590221B2 (https=) |
| EP (3) | EP3846849A1 (https=) |
| JP (3) | JP7579780B2 (https=) |
| KR (1) | KR20210071979A (https=) |
| CN (1) | CN112912106A (https=) |
| AU (4) | AU2019335006B2 (https=) |
| BR (1) | BR112021003962A2 (https=) |
| CA (1) | CA3111332A1 (https=) |
| CO (1) | CO2021003931A2 (https=) |
| DK (1) | DK3620174T3 (https=) |
| EC (1) | ECSP21023398A (https=) |
| ES (1) | ES2908304T3 (https=) |
| IL (2) | IL298307A (https=) |
| MX (1) | MX2021002586A (https=) |
| PE (1) | PE20211545A1 (https=) |
| PH (1) | PH12021550479A1 (https=) |
| SG (1) | SG11202102104SA (https=) |
| WO (1) | WO2020051334A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20231581T1 (hr) | 2013-03-15 | 2024-03-15 | Takeda Vaccines, Inc. | Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima |
| US11007261B2 (en) * | 2016-04-13 | 2021-05-18 | Takeda Vaccines, Inc. | Compositions and methods of vaccination against dengue virus in children and young adults |
| WO2020051334A1 (en) * | 2018-09-05 | 2020-03-12 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| EP4110381A1 (en) * | 2020-02-27 | 2023-01-04 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
| WO2022158097A1 (ja) * | 2021-01-19 | 2022-07-28 | 新田ゼラチン株式会社 | ウイルス安定化剤、ウイルス安定化剤用ゼラチン加水分解物およびウイルス含有組成物 |
| CN112813089A (zh) * | 2021-03-22 | 2021-05-18 | 苏州诺威百奥生物科技有限公司 | 黄病毒科检测用多位点重组抗原的制备方法 |
| CN113913551B (zh) * | 2021-06-22 | 2022-05-13 | 中国检验检疫科学研究院 | 一种登革病毒分型的测序引物、检测方法及试剂盒 |
| AU2023365824A1 (en) | 2022-10-18 | 2025-06-05 | Takeda Vaccines, Inc. | Dengue vaccine formulation |
| EP4357464A1 (en) * | 2022-10-20 | 2024-04-24 | Takeda Vaccines, Inc. | A method for detecting the presence of a dengue virus serotype in a sample containing at least one dengue virus serotype |
| EP4375381B1 (en) * | 2022-11-18 | 2026-02-25 | Takeda Vaccines, Inc. | A method for determining the proportion of a live, attenuated dengue virus having a nucleotide sequence comprising at least one attenuation locus in a formulation |
| CN120271718A (zh) * | 2024-01-05 | 2025-07-08 | 北京昌平实验室 | 针对寨卡/登革病毒的重组抗原、其疫苗组合物及其应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4810092A (en) | 1986-02-21 | 1989-03-07 | Midac Corporation | Economical spectrometer unit having simplified structure |
| JPH084508B2 (ja) | 1987-09-16 | 1996-01-24 | 国立予防衛生研究所長 | 組み換えワクチニアウイルス |
| JP2511494B2 (ja) | 1988-05-12 | 1996-06-26 | 善治 松浦 | 日本脳炎ウイルス表面抗原蛋白質の製造法 |
| US6184024B1 (en) | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
| IL91304A0 (en) | 1988-08-20 | 1990-03-19 | Us Health | Recombinant vaccinia virus for prevention of disease caused by flavivirus |
| MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
| US5514375A (en) | 1990-08-15 | 1996-05-07 | Virogenetics Corporation | Flavivirus recombinant poxvirus vaccine |
| US5494671A (en) | 1990-08-27 | 1996-02-27 | The United States Of America As Represented By The Department Of Health And Human Services | C-terminally truncated dengue and Japanese encephalitis virus envelope proteins |
| DE69231570T2 (de) | 1991-09-19 | 2001-06-21 | Us Of America Represented By D | Chimäre und/oder wachstumgehemmte Flaviviren |
| JPH05276941A (ja) | 1992-02-28 | 1993-10-26 | Nippon Zeon Co Ltd | フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法 |
| WO1996037221A1 (en) | 1995-05-24 | 1996-11-28 | Hawaii Biotechnology Group, Inc. | Subunit vaccine against flavivirus infection |
| AU6093296A (en) | 1995-06-07 | 1996-12-30 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
| HU228705B1 (en) | 1997-02-28 | 2013-05-28 | Univ St Louis | Chimeric flavivirus vaccines |
| ATE314476T1 (de) | 1997-10-08 | 2006-01-15 | Us Gov Health & Human Serv | Chimärer impfstoff gegen das zeckenenzephalitis virus |
| US7417136B1 (en) | 1998-06-04 | 2008-08-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
| EP3000477A1 (en) | 2000-02-16 | 2016-03-30 | The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, | Avirulent, immunogenic flavivirus chimeras |
| WO2002072036A2 (en) | 2001-03-12 | 2002-09-19 | Yale University | Compositions and methods comprising west nile virus polypeptides |
| US20040259224A1 (en) | 2002-05-31 | 2004-12-23 | Farshad Guirakhoo | Tetravalent Dengue vaccines |
| BRPI0613287A2 (pt) | 2005-06-17 | 2010-12-28 | Sanofi Pasteur | cepa do vìrus da dengue-2 vivo atenuada, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada codificadas pela seq id n .1 ou fragmentos desta e fragmento da poliproteìna |
| US20080193477A1 (en) | 2005-08-10 | 2008-08-14 | Acambis Inc. | Vaccination Against Dengue Virus Infection |
| FR2903605A1 (fr) | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2906724B1 (fr) | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR2909286B1 (fr) | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
| DK2178903T3 (da) | 2007-07-13 | 2012-06-18 | Florida Gulf Coast University | Optimeret denguevirus-adgangsinhiberede peptid (DN81) |
| SG157244A1 (en) | 2008-05-15 | 2009-12-29 | Mp Biomedicals Asia Pacific Pte Ltd | Point of care test for the detection of exposure or immunity to dengue virus |
| WO2010085358A2 (en) | 2009-01-23 | 2010-07-29 | The Board Of Regents Of The University Of Texas System | Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof |
| NZ597000A (en) | 2009-06-01 | 2014-07-25 | Takeda Vaccines Inc | Compositions and methods for administration of vaccines against dengue virus |
| US8968996B2 (en) | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| BRPI0904020B8 (pt) | 2009-10-01 | 2021-05-25 | Fundacao Oswaldo Cruz | composição vacinal contra o vírus da dengue, e, kit |
| EP2353609A1 (en) | 2010-02-04 | 2011-08-10 | Sanofi Pasteur | Immunization compositions and methods |
| NZ630831A (en) | 2012-06-10 | 2019-02-22 | Takeda Vaccines Inc | Compositions and methods for administration of vaccines against dengue virus |
| KR20150036593A (ko) | 2012-07-24 | 2015-04-07 | 사노피 파스퇴르 | 뎅기열 바이러스 감염 예방용 백신 조성물 |
| MX381497B (es) | 2012-07-24 | 2025-03-12 | Sanofi Pasteur | Composiciones vacuna. |
| TW201920677A (zh) | 2012-11-08 | 2019-06-01 | 美商武田疫苗股份有限公司 | 登革熱病毒血清型４型之建構物的組成物、方法及用途 |
| JP2016504315A (ja) * | 2012-12-14 | 2016-02-12 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | 三価デングウイルス製剤に関する組成物、投与方法および使用 |
| HRP20231581T1 (hr) | 2013-03-15 | 2024-03-15 | Takeda Vaccines, Inc. | Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima |
| TWI852899B (zh) | 2014-09-02 | 2024-08-21 | 法商賽諾菲巴斯德公司 | 疫苗組合物 |
| WO2017005654A1 (en) | 2015-07-03 | 2017-01-12 | Sanofi Pasteur | Concomitant dengue, diphtheria, tetanus, whooping cough (pertussis), polio, and haemophilus influenzae type b vaccination. |
| BR112017028212A2 (pt) | 2015-07-03 | 2018-09-11 | Sanofi Pasteur | vacinação concomitante contra dengue e febre amarela |
| US10004795B2 (en) | 2015-09-08 | 2018-06-26 | Fundacao Butantan | Process for preparing an attenuated tetravalent dengue vaccine |
| US11007261B2 (en) * | 2016-04-13 | 2021-05-18 | Takeda Vaccines, Inc. | Compositions and methods of vaccination against dengue virus in children and young adults |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| US11464815B2 (en) * | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| WO2020051334A1 (en) * | 2018-09-05 | 2020-03-12 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
-
2019
- 2019-09-05 WO PCT/US2019/049749 patent/WO2020051334A1/en not_active Ceased
- 2019-09-05 JP JP2021512482A patent/JP7579780B2/ja active Active
- 2019-09-05 AU AU2019335006A patent/AU2019335006B2/en active Active
- 2019-09-05 MX MX2021002586A patent/MX2021002586A/es unknown
- 2019-09-05 EP EP19769699.0A patent/EP3846849A1/en active Pending
- 2019-09-05 US US16/561,953 patent/US11590221B2/en active Active
- 2019-09-05 DK DK19195692.9T patent/DK3620174T3/da active
- 2019-09-05 CN CN201980070866.0A patent/CN112912106A/zh active Pending
- 2019-09-05 EP EP22151940.8A patent/EP4082568A1/en active Pending
- 2019-09-05 EP EP19195692.9A patent/EP3620174B1/en active Active
- 2019-09-05 US US17/274,016 patent/US20220226401A1/en active Pending
- 2019-09-05 SG SG11202102104SA patent/SG11202102104SA/en unknown
- 2019-09-05 IL IL298307A patent/IL298307A/en unknown
- 2019-09-05 KR KR1020217009759A patent/KR20210071979A/ko active Pending
- 2019-09-05 CA CA3111332A patent/CA3111332A1/en active Pending
- 2019-09-05 ES ES19195692T patent/ES2908304T3/es active Active
- 2019-09-05 PE PE2021000288A patent/PE20211545A1/es unknown
- 2019-09-05 BR BR112021003962-7A patent/BR112021003962A2/pt unknown
- 2019-09-05 IL IL281177A patent/IL281177B2/en unknown
-
2021
- 2021-03-05 PH PH12021550479A patent/PH12021550479A1/en unknown
- 2021-03-29 CO CONC2021/0003931A patent/CO2021003931A2/es unknown
- 2021-04-05 EC ECSENADI202123398A patent/ECSP21023398A/es unknown
-
2023
- 2023-01-04 US US18/149,742 patent/US20230355748A1/en active Pending
-
2024
- 2024-04-03 JP JP2024060499A patent/JP7791925B2/ja active Active
- 2024-09-26 AU AU2024220111A patent/AU2024220111B9/en active Active
-
2025
- 2025-07-07 AU AU2025205182A patent/AU2025205182B1/en active Active
- 2025-10-21 JP JP2025177428A patent/JP2026031938A/ja active Pending
- 2025-12-10 AU AU2025279696A patent/AU2025279696A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211545A1 (es) | Dosis unitaria de vacuna contra el dengue y administracion de esta | |
| MX2018014573A (es) | Vacuna contra el virus del zika. | |
| CO6270337A2 (es) | Vacuna viva avirulenta de mycoplama hyopneumoniae con adyuvante | |
| MX2020001052A (es) | Formulaciones de anticuerpos anti-c5 de alta concentracion. | |
| PE20151588A1 (es) | Vacuna contra el virus del dengue | |
| AR127585A1 (es) | Vacuna de arn de virus sincicial respiratorio | |
| AR055603A1 (es) | Vacuna contra la infeccion por virus del dengue | |
| CL2017001961A1 (es) | Vacuna bivalente contra el virus de gripe porcina | |
| AR064009A1 (es) | Metodo de inmunizacion contra los 4 serotipos del dengue | |
| AR089797A1 (es) | Vacunas contra clostridum difficile que comprenden toxinas recombinantes | |
| AR108829A1 (es) | Vacuna contra virus de bronquitis infecciosa | |
| MX378901B (es) | Formulaciones liquidas estables de virus de vacuna. | |
| PE20140646A1 (es) | Vacuna de virus de dengue inactivado | |
| MX2017005687A (es) | Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia. | |
| AR106026A1 (es) | Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos | |
| CO2022014152A2 (es) | Vacuna contra el virus de la peste porcina africana | |
| BR112015021523A8 (pt) | composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis | |
| MX2023012390A (es) | Vacunacion con particulas de replicon y adyuvante oleoso. | |
| CO2023003242A2 (es) | Vacuna contra el coronavirus y procedimiento para la preparación de la misma | |
| MX2020005235A (es) | Celula humana transformada y uso de la misma. | |
| ECSP18081582A (es) | Constructos de alfavirus vivo atenuado y métodos y usos de los mismos | |
| MX2017009306A (es) | Vacuna contra la fiebre aftosa. | |
| BR112016002354A2 (pt) | composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit | |
| CL2007002710A1 (es) | Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs. | |
| MX2015013115A (es) | Nuevos regimenes de dosificacion de celgosivir para el tratamiento de dengue. |